Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone.

ABSTRACT:

Background

Genetic variations in Idiopathic Pulmonary Fibrosis (IPF) affect survival and outcomes. Current antifibrotic agents are managed based on the patient's reported side effects, although certain single nucleotide polymorphisms (SNPs) might alter treatment response and survival depending on the antifibrotic administered. This study investigated variations in response and outcomes to pirfenidone based on patients-specific genetic profiles.

Methods

Retrospective clinical data were collected from 56 IPF patients and had blood drawn for DNA extraction between 7/2013 and 3/2016, with the last patient followed until 10/2018. Nine SNPs were selected for pharmacogenetic investigation based on prior associations with IPF treatment outcomes or implications for pirfenidone metabo

SUBMITTER: Kubbara A 

PROVIDER: S-EPMC10407116 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature